drugset / Trial / NCT07824934
HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I Study of HEC-921 Injection as Monotherapy and in Combination with Other AntineoplasticTherapy in Patients with Advanced Malignant Solid Tumors
Timeline
- Start
- 2026-09-18
- Primary completion
- 2028-05
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | HEC-921 | Unknown | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |